{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:22:22Z","timestamp":1747207342176,"version":"3.40.5"},"reference-count":38,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p\/>\n<\/jats:sec>","DOI":"10.2174\/1573397118666220308160124","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T05:38:30Z","timestamp":1647236310000},"page":"279-285","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["What is the Place for Uricosuric Agents in Gout Management?"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9964-599X","authenticated-orcid":true,"given":"Md Abu Bakar","family":"Siddiq","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rheumatology, Brahmanbaria Medical College, Brahmanbaria, Bangladesh"},{"name":"School of Health Sport and Professional Practice, University of South Wales, Pontypridd, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim L.","family":"Jansen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Viecuri MC, Venlo, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes J.","family":"Rasker","sequence":"additional","affiliation":[{"name":"Faculty of Behavioral, Management and Social Sciences, Department Psychology, Health and Technology, University of Twente, Enschede, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(16)31460-X","volume":"388","author":"Kassebaum N.J.","year":"2016","unstructured":"Kassebaum N.J.; Arora M.; Barber R.M.; Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016,388(10053),1603-1658","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/rheumatology\/kex349","volume":"57","author":"So A.","year":"2018","unstructured":"So A.; Dumusc A.; Nasi S.; The role of IL-1 in gout: From bench to bedside. Rheumatology (Oxford) 2018,57(Suppl. 1),i12-i19","journal-title":"Rheumatology (Oxford)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/ard.46.1.72","volume":"46","author":"ter Borg E.J.","year":"1987","unstructured":"ter Borg E.J.; Rasker J.J.; Gout in the elderly, a separate entity? Ann Rheum Dis 1987,46(1),72-76","journal-title":"Ann Rheum Dis"},{"key":"ref=4","first-page":"1032","volume":"29","author":"Jansen T.L.","year":"2011","unstructured":"Jansen T.L.; Rasker J.J.; Crystal -induced arthritis, a review for clinicians. Clin Exp Rheumatol 2011,29(6),1032-1039","journal-title":"Clin Exp Rheumatol"},{"key":"ref=5","first-page":"2437","volume":"30","author":"Darmawan J.","year":"2003","unstructured":"Darmawan J.; Rasker J.J.; Nuralim H.; The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years. J Rheumatol 2003,30(11),2437-2443","journal-title":"J Rheumatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"Khanna D.","year":"2012","unstructured":"Khanna D.; Fitzgerald J.D.; Khanna P.P.; 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012,64(10),1431-1446","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"Richette P.","year":"2017","unstructured":"Richette P.; Doherty M.; Pascual E.; 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017,76(1),29-42","journal-title":"Ann Rheum Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","volume":"76","author":"Kiltz U.","year":"2017","unstructured":"Kiltz U.; Smolen J.; Bardin T.; Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis 2017,76(4),632-638","journal-title":"Ann Rheum Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"FitzGerald J.D.","year":"2020","unstructured":"FitzGerald J.D.; Dalbeth N.; Mikuls T.; 2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 2020,72(6),744-760","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1136\/ard.2008.091462","volume":"68","author":"Reinders M.K.","year":"2009","unstructured":"Reinders M.K.; Haagsma C.; Jansen T.L.; A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout. Ann Rheum Dis 2009,68(6),892-897","journal-title":"Ann Rheum Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","volume":"12","author":"Stamp L.K.","year":"2016","unstructured":"Stamp L.K.; Day R.O.; Yun J.; Allopurinol hypersensitivity: Investigating the cause and minimizing the risk. Nat Rev Rheumatol 2016,12(4),235-242","journal-title":"Nat Rev Rheumatol"},{"key":"ref=12","first-page":"651","volume":"22","author":"Jansen T.L.","year":"2004","unstructured":"Jansen T.L.; Reinders M.K.; van Roon E.N.; Brouwers J.R.; Benzbromarone withdrawn from the European market: Another case of &#x201C;absence of evidence is evidence of absence&#x201D;? Clin Exp Rheumatol 2004,22(5),651","journal-title":"Clin Exp Rheumatol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/ard.2007.083071","volume":"68","author":"Reinders M.K.","year":"2009","unstructured":"Reinders M.K.; van Roon E.N.; Jansen T.L.; Efficacy and tolerability of urate-lowering drugs in gout: A randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009,68(1),51-56","journal-title":"Ann Rheum Dis"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","volume":"26","author":"Reinders M.K.","year":"2007","unstructured":"Reinders M.K.; van Roon E.N.; Houtman P.M.; Brouwers J.R.; Jansen T.L.; Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 2007,26(9),1459-1465","journal-title":"Clin Rheumatol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/1759720X16646703","volume":"8","author":"Sattui S.E.","year":"2016","unstructured":"Sattui S.E.; Gaffo A.L.; Treatment of hyperuricemia in gout: Current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis 2016,8(4),145-159","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1007\/s10067-018-4306-9","volume":"37","author":"Jansen T.L.","year":"2018","unstructured":"Jansen T.L.; Perez-Ruiz F.; Tausche A.K.; Richette P.; International position paper on the appropriate use of uricosurics with the introduction of lesinurad. Clin Rheumatol 2018,37(12),3159-3165","journal-title":"Clin Rheumatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","volume":"56","author":"Tausche A.K.","year":"2017","unstructured":"Tausche A.K.; Alten R.; Dalbeth N.; Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: A 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford) 2017,56(12),2170-2178","journal-title":"Rheumatology (Oxford)"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/art.39840","volume":"69","author":"Saag K.G.","year":"2017","unstructured":"Saag K.G.; Fitz-Patrick D.; Kopicko J.; Lesinurad combined with allopurinol: Randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (a US-based Study). Arthritis Rheumatol 2017,69(1),203-212","journal-title":"Arthritis Rheumatol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","volume":"76","author":"Bardin T.","year":"2017","unstructured":"Bardin T.; Keenan R.T.; Khanna P.P.; Lesinurad in combination with allopurinol: A randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis 2017,76(5),811-820","journal-title":"Ann Rheum Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/art.40159","volume":"69","author":"Dalbeth N.","year":"2017","unstructured":"Dalbeth N.; Jones G.; Terkeltaub R.; Lesinurad, a Selective uric acid reabsorption inhibitor, in combination with febuoxstat in patients with tophaceous gout: Findings of a Phase III Clinical Trial. Arthritis Rheumatol 2017,69(9),1903-1913","journal-title":"Arthritis Rheumatol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1136\/annrheumdis-2016-210519","volume":"76","author":"Singh J.A.","year":"2017","unstructured":"Singh J.A.; Lesinurad combination therapy with allopurinol in gout: Do clear studies make the treatment of gout clearer? Ann Rheum Dis 2017,76(5),779-781","journal-title":"Ann Rheum Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13075-018-1788-4","volume":"21","author":"Dalbeth N.","year":"2019","unstructured":"Dalbeth N.; Jones G.; Terkeltaub R.; Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: Crystal extension study. Arthritis Res Ther 2019,21(1),8","journal-title":"Arthritis Res Ther"},{"key":"ref=23","unstructured":"Lesinurad - AstraZenecaAvailable from:    (Accessed on August, 2021)."},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41598-017-00706-7","volume":"7","author":"Tan P.K.","year":"2017","unstructured":"Tan P.K.; Liu S.; Gunic E.; Miner J.N.; Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep 2017,7(1),665","journal-title":"Sci Rep"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1080\/14397595.2018.1538003","volume":"29","author":"Fitz-Patrick D.","year":"2019","unstructured":"Fitz-Patrick D.; Roberson K.; Niwa K.; Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials. Mod Rheumatol 2019,29(6),1042-1052","journal-title":"Mod Rheumatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.ajkd.2020.09.009","volume":"77","author":"Stack A.G.","year":"2021","unstructured":"Stack A.G.; Dronamraju N.; Parkinson J.; Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: A randomized trial. Am J Kidney Dis 2021,77(4),481-489","journal-title":"Am J Kidney Dis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e2347","DOI":"10.1210\/clinem\/dgaa748","volume":"106","author":"Stack A.G.","year":"2021","unstructured":"Stack A.G.; Han D.; Goldwater R.; Dapagliflozin added to verinurad plus febuxostat further reduces serum uric acid in hyperuricemia: The quartz study. J Clin Endocrinol Metab 2021,106(5),e2347-e2356","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14428","volume":"13","author":"Iqbal A.","year":"2021","unstructured":"Iqbal A.; Iqbal K.; Farid E.; Efficacy and safety of dotinurad in hyperuricemic patients with or without gout: A systematic review and meta-analysis of randomized controlled trials. Cureus 2021,13(4)","journal-title":"Cureus"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1080\/10641963.2021.1950752","volume":"43","author":"Takahashi T.","year":"2021","unstructured":"Takahashi T.; Beppu T.; Hidaka Y.; Hosoya T.; Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: A pooled analysis of individual participant data in phase II and III trials. Clin Exp Hypertens 2021,43(8),730-741","journal-title":"Clin Exp Hypertens"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10157-019-01818-2","volume":"24","author":"Hosoya T.","year":"2020","unstructured":"Hosoya T.; Sano T.; Sasaki T.; Fushimi M.; Ohashi T.; Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: Randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. Clin Exp Nephrol 2020,24(S1)(Suppl. 1),53-61","journal-title":"Clin Exp Nephrol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s42358-019-0080-x","volume":"59","author":"Azevedo V.F.","year":"2019","unstructured":"Azevedo V.F.; Kos I.A.; Vargas-Santos A.B.; da Rocha Castelar Pinheiro G.; Dos Santos Paiva E.; Benzbromarone in the treatment of gout. Adv Rheumatol 2019,59(1),37","journal-title":"Adv Rheumatol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/2040622312462056","volume":"3","author":"Burns C.M.","year":"2012","unstructured":"Burns C.M.; Wortmann R.L.; Latest evidence on gout management: What the clinician needs to know. Ther Adv Chronic Dis 2012,3(6),271-286","journal-title":"Ther Adv Chronic Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/psb.1238","volume":"5","author":"Jordan K.","year":"2014","unstructured":"Jordan K.; Jeffries A.; Current treatment options for acute and chronic gout. Prescriber 2014,5(17),25-34","journal-title":"Prescriber"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2217\/cer-2017-0103","volume":"7","author":"Klein R.W.","year":"2018","unstructured":"Klein R.W.; Kabadi S.; Cinfio F.N.; Bly C.A.; Taylor D.C.A.; Szymanski K.A.; Budget impact of adding lesinurad for second-line treatment of gout: A US health plan perspective. J Comp Eff Res 2018,7(8),807-816","journal-title":"J Comp Eff Res"},{"key":"ref=35","first-page":"374","volume":"97","author":"On P.C.","year":"2018","unstructured":"On P.C.; Lesinurad (Zurampic) for Gout. Am Fam Physician 2018,97(6),374-375","journal-title":"Am Fam Physician"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"White W.B.","year":"2018","unstructured":"White W.B.; Saag K.G.; Becker M.A.; Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018,378(13),1200-1210","journal-title":"N Engl J Med"},{"key":"ref=37","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1076189","volume":"2019","author":"Cuenca J.A.","year":"2019","unstructured":"Cuenca J.A.; Balda J.; Palacio A.; Young L.; Pillinger M.H.; Tamariz L.; Febuxostat and cardiovascular events: A systematic review and meta-analysis. Int J Rheumatol 2019,2019","journal-title":"Int J Rheumatol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13075-019-1976-x","volume":"21","author":"Liang N.","year":"2019","unstructured":"Liang N.; Sun M.; Sun R.; Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: A prospective, randomized controlled study in a Chinese primary gout cohort. Arthritis Res Ther 2019,21(1),200","journal-title":"Arthritis Res Ther"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397118666220308160124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/201911\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397118666220308160124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T07:02:23Z","timestamp":1669100543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/201911\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573397118666220308160124","relation":{},"ISSN":["1573-3971"],"issn-type":[{"type":"print","value":"1573-3971"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}